ADRB2 and squamous cell carcinoma: Based on known agonism activity and lipophilicity, four β2-agonists were chosen to characterize the ligand-selective desensitization in A431, a human epidermoid carcinoma cell line that endogenously expresses β2AR, but not other adrenergic receptors [28].